%0 Journal Article
%T Posterior reversible encephalopathy syndrome (PRES) attributed to mycophenolate mofetil during the management of SLE: a case report and review
%A Jian Xu
%A Lei Zhang
%J Archive of "American Journal of Clinical and Experimental Immunology".
%D 2018
%X Posterior reversible encephalopathy syndrome (PRES) is a rare clinical entity associated with systemic lupus erythematosus which characterized by seizure, headache, and altered mental status. The pathophysiology involves subcortical vasogenic edema secondary to hypertension and endothelial damage. PRES is reversible with withdrawal of the offending agent, strict blood pressure control, and treating the underlying disease. We report present here a patient with lupus nephritis who developed PRES following mycophenolate administration
%K Posterior reversible encephalopathy syndrome
%K mycophenolate mofetil
%K systemic lupus erythematosus
%K adverse drug event
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840284/